Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance profiles in patients with viral rebound on potent antiretroviral therapy.

The Journal of infectious diseases - 1 Mar 2000

Cozzi Lepri A, Sabin C A, Staszewski S, Hertogs K, Müller A, Rabenau H, Phillips A N, Miller V

Abstract excerpt

The prevalence of phenotypic drug resistance was assessed in 60 patients with a viral rebound after they received a protease inhibitor (PI)- or nonnucleoside reverse transcriptase inhibitor (NNRTI)-containing regimen (baseline). Resistance testing was done within 36 weeks of viral rebound; no resistance testing was available at baseline. All patients had previously received zidovudine; 86.0% had received...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance
Share to HIV Infections
Share to HIV Protease Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Phenotype

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 10720543
DOI: 10.1086/315301

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance profiles in patients with viral rebound on potent antiretroviral therapy.PMID 10720543Read ↗

HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.Semantic proximity Read ↗

Current management challenges in HIV: antiretroviral resistance.Semantic proximity Read ↗

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.Semantic proximity Read ↗

Antiretroviral resistance during successful therapy of HIV type 1 infection.Semantic proximity Read ↗

Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml.Semantic proximity Read ↗

Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy.Semantic proximity Read ↗

Reversal periods and patterns from drug-resistant to wild-type HIV type 1 after cessation of anti-HIV therapy.Semantic proximity Read ↗

Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.Semantic proximity Read ↗

Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.Semantic proximity Read ↗

Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients.Semantic proximity Read ↗

Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.Semantic proximity Read ↗

Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.